Complete Genomics Inc Revenue Growth Rates (GNOM), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Complete Genomics Inc  (GNOM)
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare
 

GNOM's Revenue Growth by Quarter and Year

Complete Genomics Inc's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

GNOM Revenue (in millions $) FY 2012 FY 2011 FY 2010 FY 2009
4th Quarter December -
3rd Quarter September 7.28
2nd Quarter June 8.69
1st Quarter March 3.91
FY 19.88





GNOM Revenue third quarter 2012 Y/Y Growth Comment
Complete Genomics Inc achieved in the third quarter 2012, above Company average Revenue rise of 74.07% year on year, to $ 7.28 millions.

Among companies who have reported third quarter 2012 results in the Medical Laboratories industry only one Company has achieved higher year on year Revenue results in the third quarter 2012. While Complete Genomics Inc' s Revenue jump of 74.07% ranks overall at the positon no. 713 in the third quarter 2012.


GNOM Revenue ( Y/Y Growth %) 2012
 2011 2010 2009
4th Quarter December - -40.63 % - -
3rd Quarter September 74.07 % 283.49 % - -
2nd Quarter June 48.04 % - - -
1st Quarter March -42.75 % - - -
FY   - 268.57 % - -

Financial Statements
Complete Genomics Inc's third quarter 2012 Revenue $ 7.28 millions GNOM's Income Statement
Complete Genomics Inc's third quarter 2011 Revenue $ 4.18 millions Quarterly GNOM's Income Statement


GNOM Revenue (Quarter on Quarter Growth %)

 2012
 2011 2010 2009
4th Quarter December - -40.91 % 281.65 % -
3rd Quarter September -16.27 % -28.79 % - -
2nd Quarter June 122.25 % -14.06 % - -
1st Quarter March 58.3 % 64.18 % - -
FY (Year on Year)   - 268.57 % - -


Back to GNOM Growth rate Comparisons >> Back to GNOM Growth rate Comparisons >>


Revenue third quarter 2012 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #2
Healthcare Sector #100
Overall #713

Revenue Y/Y Growth Statistics
High Average Low
7.24 % 6.73 % 6.23 %
(Jun 30 2012)   (Sep 30 2012)
Revenue third quarter 2012 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #2
Healthcare Sector #100
Overall #713
Revenue Y/Y Growth Statistics
High Average Low
7.24 % 6.73 % 6.23 %
(Jun 30 2012)   (Sep 30 2012)

Revenue by Quarter for the Fiscal Years 2009, 2010, 2011, 2012

Complete Genomics Inc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
122.44 % 53.07 % -16.3 %
(Jun 30 2012)  


GNOM's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2012 Complete Genomics Inc disclosed fall in Revenue from the second quarter by -16.27% to $ 7.28 millions, from $ 8.69 millions achived in the previous reporting period.

But that's not important problem, as Complete Genomics Inc's Revenue generally seem to plunge in this quarter.

Within Medical Laboratories industry 20 other companies have achieved higher Revenue quarter on quarter growth. While Complete Genomics Inc's Revenue growth quarter on quarter, overall rank is 3144.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #21
Healthcare Sector #329
Overall #3144
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #21
Healthcare Sector #329
Overall #3144
Revenue Q/Q Growth Statistics
High Average Low
122.44 % 53.07 % -16.3 %
(Jun 30 2012)  


GNOM's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2012 Complete Genomics Inc disclosed fall in Revenue from the second quarter by -16.27% to $ 7.28 millions, from $ 8.69 millions achived in the previous reporting period.

But that's not important problem, as Complete Genomics Inc's Revenue generally seem to plunge in this quarter.

Within Medical Laboratories industry 20 other companies have achieved higher Revenue quarter on quarter growth. While Complete Genomics Inc's Revenue growth quarter on quarter, overall rank is 3144.


Complete Genomics Inc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2012)		 12 Months Ending
(Jun 30 2012)		 12 Months Ending
(Mar 31 2012)		 12 Months Ending
(Dec 31 2011)		 12 Months Ending
Cumulative Revenue 12 Months Ending $ 22.35 $ 19.25 $ 0.00 $ 0.00 $ 0.00
Y / Y Revenue Growth (TTM) 6.23 % 7.24 % - - -
Year on Year Revenue Growth Overall Ranking # 1233 # 0 # 0 # 0 # 0
Seqeuential Revenue Change (TTM) 16.1 % 17.22 % - - -
Seq. Revenue Growth (TTM) Overall Ranking # 713 # 0 # 0 # 0 # 0


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2012 period, Complete Genomics Inc's cumulative twelve months Revenue were $ 22 millions, company would post below average annual Revenue growth of 17.22% year on year, if the fiscal year would end at Sep 30 2012.
A slow-down in the Complete Genomics Inc's Revenue growth from the 8.69% growth in Jun 30 2012. Comparing the results with it's peers in Medical Laboratories industry, Complete Genomics Inc's trailing twelve months Revenue growth, were the second highest.

In the Healthcare sector 151 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 1233.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 2
Healthcare Sector # 152
Overall # 1233

Revenue TTM Y/Y Growth Statistics
High Average Low
7.24 %
 6.73 %
6.23 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 2
Sector # 100
S&P 500 # 713
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2012 period, Complete Genomics Inc's cumulative twelve months Revenue were $ 22 millions, company would post below average annual Revenue growth of 6.23% year on year, if the fiscal year would end at Sep 30 2012.
A slow-down in the Complete Genomics Inc's Revenue growth from the 8.69% growth in Jun 30 2012. Comparing the results with it's peers in Medical Laboratories industry, Complete Genomics Inc's trailing twelve months Revenue growth, were the second highest.

In the Healthcare sector 151 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 1233.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 2
Healthcare Sector # 152
Overall # 1233

Revenue TTM Y/Y Growth Statistics
High Average Low
7.24 %
6.73 %
6.23 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 2
Sector # 100
S&P 500 # 713




Other Revenue Growth
Medical Laboratories Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
GNOM's Revenue Growth Ratio versus Medical Laboratories Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue fall for the quarter ending Sep 30 2012 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2012
Pacira Biosciences inc 114.51%$ 114.510 millions
Metropolitan Health Networks Inc106.28%$ 106.280 millions
Lisata Therapeutics Inc 103.67%$ 103.673 millions
Vivosim Labs Inc 102.26%$ 102.258 millions
Assertio Holdings inc 101.44%$ 101.441 millions
Achari Ventures Holdings Corp I94.87%$ 94.872 millions
Therapeuticsmd Inc 92.08%$ 92.079 millions
Savient Pharmaceuticals Inc90.47%$ 90.469 millions
Akorn Inc89.72%$ 89.723 millions
Insite Vision Inc83.56%$ 83.563 millions
Repligen Corp74.99%$ 74.992 millions
Complete Genomics Inc74.19%$ 74.192 millions
Axogen inc 73.64%$ 73.637 millions
Opko Health Inc 73.28%$ 73.278 millions
Alkermes Plc 72.24%$ 72.244 millions
Palisade Bio Inc 65.22%$ 65.216 millions
Gadsden Properties, Inc.63.13%$ 63.134 millions
Immunogen inc 61.32%$ 61.317 millions
Biomimetic Therapeutics, Inc.60.68%$ 60.678 millions
Natus Medical Inc57.24%$ 57.240 millions
Ds Healthcare Group, Inc.54.71%$ 54.710 millions
Pacific Health Care Organization Inc53.49%$ 53.494 millions
Prestige Consumer Healthcare Inc 53.35%$ 53.353 millions
Grapefruit Usa Inc 52.37%$ 52.374 millions
Quantrx Biomedical Corporation51.13%$ 51.125 millions
Sangui Biotech International Inc50.00%$ 50.000 millions
Bolt Biotherapeutics Inc 49.06%$ 49.060 millions
Nephros Inc 48.40%$ 48.403 millions
Igc Pharma Inc 48.17%$ 48.171 millions
Bausch Health Companies Inc 47.21%$ 47.213 millions


About Complete Genomics Inc Revenue Growth Rates (GNOM), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: the company’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.